Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Creative Capital Management Investments LLC

Creative Capital Management Investments LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,958 shares of the biopharmaceutical company’s stock after buying an additional 393 shares during the period. Creative Capital Management Investments LLC’s holdings in Gilead Sciences were worth $366,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Avior Wealth Management LLC lifted its stake in Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after acquiring an additional 108 shares in the last quarter. Southland Equity Partners LLC increased its holdings in shares of Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 110 shares during the last quarter. Concord Asset Management LLC VA grew its holdings in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 111 shares in the last quarter. Berkshire Bank grew its holdings in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 111 shares in the last quarter. Finally, TFB Advisors LLC grew its holdings in Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after buying an additional 116 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 1.8 %

Shares of Gilead Sciences stock opened at $104.08 on Tuesday. The stock has a fifty day simple moving average of $93.87 and a 200 day simple moving average of $87.70. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $106.69. The company has a market capitalization of $129.71 billion, a P/E ratio of 1,156.44, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GILD. Wolfe Research began coverage on Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price for the company. Barclays lifted their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Finally, Truist Financial lifted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $101.33.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 710,500 shares of company stock worth $67,684,956 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.